Switch theme
Sign up to access all valuation multiples
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company’s core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.
1999
274
LTM Revenue $102M
LTM EBITDA $25.2M
$694M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surgical Science has a last 12-month revenue (LTM) of $102M and a last 12-month EBITDA of $25.2M.
In the most recent fiscal year, Surgical Science achieved revenue of $91.2M and an EBITDA of $23.1M.
Surgical Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surgical Science valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $102M | XXX | $91.2M | XXX | XXX | XXX |
| Gross Profit | $60.7M | XXX | $61.7M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $25.2M | XXX | $23.1M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $18.2M | XXX | $14.9M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $16.4M | XXX | $13.6M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Surgical Science's stock price is SEK 144 (or $15).
Surgical Science has current market cap of SEK 7.3B (or $757M), and EV of SEK 6.7B (or $694M).
See Surgical Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $694M | $757M | XXX | XXX | XXX | XXX | $0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Surgical Science has market cap of $757M and EV of $694M.
Surgical Science's trades at 7.6x EV/Revenue multiple, and 30.0x EV/EBITDA.
Equity research analysts estimate Surgical Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Surgical Science has a P/E ratio of 46.2x.
See valuation multiples for Surgical Science and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $757M | XXX | $757M | XXX | XXX | XXX |
| EV (current) | $694M | XXX | $694M | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBITDA | 27.6x | XXX | 30.0x | XXX | XXX | XXX |
| EV/EBIT | 38.3x | XXX | 46.6x | XXX | XXX | XXX |
| EV/Gross Profit | 11.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 46.2x | XXX | 55.8x | XXX | XXX | XXX |
| EV/FCF | 61.0x | XXX | 75.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSurgical Science's last 12 month revenue growth is 24%
Surgical Science's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Surgical Science's rule of 40 is 61% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Surgical Science's rule of X is 85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Surgical Science and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | 61% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 85% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surgical Science acquired XXX companies to date.
Last acquisition by Surgical Science was XXXXXXXX, XXXXX XXXXX XXXXXX . Surgical Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Surgical Science founded? | Surgical Science was founded in 1999. |
| Where is Surgical Science headquartered? | Surgical Science is headquartered in Sweden. |
| How many employees does Surgical Science have? | As of today, Surgical Science has 274 employees. |
| Who is the CEO of Surgical Science? | Surgical Science's CEO is Mr. Gisli Hennermark. |
| Is Surgical Science publicy listed? | Yes, Surgical Science is a public company listed on STO. |
| What is the stock symbol of Surgical Science? | Surgical Science trades under SUS ticker. |
| When did Surgical Science go public? | Surgical Science went public in 2017. |
| Who are competitors of Surgical Science? | Similar companies to Surgical Science include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Surgical Science? | Surgical Science's current market cap is $757M |
| What is the current revenue of Surgical Science? | Surgical Science's last 12 months revenue is $102M. |
| What is the current revenue growth of Surgical Science? | Surgical Science revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Surgical Science? | Current revenue multiple of Surgical Science is 6.8x. |
| Is Surgical Science profitable? | Yes, Surgical Science is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Surgical Science? | Surgical Science's last 12 months EBITDA is $25.2M. |
| What is Surgical Science's EBITDA margin? | Surgical Science's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Surgical Science? | Current EBITDA multiple of Surgical Science is 27.6x. |
| What is the current FCF of Surgical Science? | Surgical Science's last 12 months FCF is $11.4M. |
| What is Surgical Science's FCF margin? | Surgical Science's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Surgical Science? | Current FCF multiple of Surgical Science is 61.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
